Harmful Reactions Linked to Counterfeit "Botox" or Mishandled Botulinum Toxin Injections

What to know

Investigation start date: April 19, 2024
Investigation status: Closed
Recall issued: No

Update as of December 17, 2024: Earlier this year, public health officials investigated reports of harmful reactions among people who received botulinum toxin injections. These people reported harmful reactions after receiving injections of unsafe counterfeit products or injections from individuals who were not following state or local requirements. Some of these products were purchased through large online marketplaces instead of through authorized suppliers of FDA-approved products.

Although this investigation is closed, CDC continues to receive reports of similar cases, including at least four harmful reactions in August and September linked to counterfeit botulinum toxin products. Some products were self-injected.

Only get botulinum toxin injections if the product is obtained from an authorized supplier and the provider is licensed and trained to give the injection. If in doubt, don't get the injection.

Fast Facts

United States
  • Cases: 17
  • Hospitalizations: 13
  • Deaths: 0
  • States: 9

Investigation Summary

Data show that injections of counterfeit or mishandled botulinum toxin (commonly called "Botox") made people sick.

  • Some people received injections with counterfeit products or products with unverified sources.
  • Some people received injections from individuals who did not follow jurisdictional (state or local) requirements.

FDA's drug safety announcement includes images of counterfeit products and authentic, FDA-approved products.

What you should do

If you are considering an injection of botulinum toxin for a medical condition or cosmetic reason (such as for wrinkles):

  • Ask your provider if they are licensed and trained to give the injection.
    • Your state might have a look-up tool where you can check whether a provider or, if required, a setting (such as a clinic or spa) has the appropriate license.
  • Ask if the botulinum toxin product is approved by FDA and obtained from a reliable source.
  • If in doubt, don't get the injection.

See your healthcare provider or go to the emergency room immediately if you have any symptoms of botulism, including

  • Blurry or double vision
  • Drooping eyelids
  • Difficulty swallowing
  • Difficulty breathing
  • Muscle weakness

Report problems you might have to the U.S. Food and Drug Administration (FDA).

What healthcare providers should do

  • Consider the possibility of adverse effects from botulinum toxin injection, including for cosmetic reasons, when patients present with signs and symptoms consistent with botulism near the injection site.
  • Be aware of symptom overlap between the presentation of localized adverse effects from injection of botulinum toxin and the early symptoms of botulism. To help distinguish early botulism symptoms from localized adverse effects:
    • Assess for symmetry of cranial nerve palsies; symmetric cranial nerve palsies are expected with botulism.
    • Assess for progression of cranial nerve palsies, possibly followed by a descending symmetric flaccid paralysis. These should raise suspicion for botulism.
  • If systemic botulism is suspected, call your health department immediately for consultation and antitoxin release. If no one answers, contact the CDC Botulism Consultation Service 24/7 at 770-488-7100.
    • Refer to your state or local health department for guidance on reporting adverse effects.
  • Counsel patients who report using or being interested in using botulinum toxin about the risks of botulism and possible adverse events.
  • Encourage patients to receive injections only from licensed providers who are trained in proper administration of FDA-approved botulinum toxin and practicing in accordance with state and local requirements.
  • Report harmful reactions related to the use of any medication, including suspected counterfeit medication, to FDA's MedWatch Safety Information and Adverse Event Reporting Program.